Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preclinical data for Droloxifene

M Hasmann1, B Rattel, R Löser

  • 1Department of Pharmacology and Toxicology, Klinge Pharma GmbH, Munich, Germany.

Cancer Letters
|September 15, 1994
PubMed
Summary

Droloxifene demonstrates superior efficacy and safety over Tamoxifen in inhibiting estrogen receptor-positive breast cancer growth. This new antiestrogen shows higher binding affinity, better tolerability, and reduced toxicity, making it a promising option for breast cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Leukemia·2017
Same author

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Leukemia·2016
Same author

Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.

Pharmacology & therapeutics·2014
Same author

Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs.

Oncogenesis·2013
Same author

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

Leukemia·2012

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Estrogen receptor (ER) signaling is a key driver in many breast cancers.
  • Tamoxifen is a widely used antiestrogen therapy, but its efficacy and side effect profile can be improved.

Purpose of the Study:

  • To evaluate the efficacy and safety of the novel antiestrogen Droloxifene compared to Tamoxifen in ER-positive breast cancer models.
  • To investigate the molecular mechanisms underlying Droloxifene's anti-cancer effects.

Main Methods:

  • In vitro studies using ER-positive human breast cancer cell lines to assess binding affinity, growth inhibition, and cell cycle effects.
  • In vivo studies using animal tumor models (R3230AC, 13762, T61) to evaluate anti-tumor activity.
  • Toxicological assessments including carcinogenicity, mutagenicity, and estrogenicity studies.

Main Results:

  • Droloxifene exhibits 10-60 fold higher ER binding affinity than Tamoxifen.
  • Droloxifene demonstrates superior inhibition of ER-positive breast cancer cell growth and tumor progression in vitro and in vivo.
  • Droloxifene effectively induces TGF-beta, inhibits IGF-I, and prevents c-myc expression, unlike Tamoxifen.
  • Droloxifene shows significantly lower toxicity, with no carcinogenic or mutagenic effects, compared to Tamoxifen.

Conclusions:

  • Droloxifene represents a significant advancement over Tamoxifen for treating ER-positive breast cancer due to its enhanced efficacy and improved safety profile.
  • Its potent antiestrogenic activity, favorable tolerability, and lack of genotoxicity suggest Droloxifene as a safer and more effective therapeutic option, particularly for long-term adjuvant or preventive treatment.

Related Experiment Videos